BioMarin Pharma (BMRN) Tops Q3 EPS by 13c, Revenue Misses
Get Alerts BMRN Hot Sheet
Price: $90.07 --0%
Revenue Growth %: +8.9%
Financial Fact:
Interest expense: -9.98M
Today's EPS Names:
MAXN, CSTR, ACU, More
Revenue Growth %: +8.9%
Financial Fact:
Interest expense: -9.98M
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.26), $0.13 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $279.9 million versus the consensus estimate of $289.44 million.
Updated 2016 Financial Guidance
Revenue Guidance ($ in millions)
Item | ||||
Provided August 4, 2016 | Updated October 27, 2016 | |||
Total BioMarin Revenues | $1,100 to $1,150 | Unchanged | ||
Vimizim Net Product Revenues | $340 to $360 | Unchanged | ||
Naglazyme Net Product Revenues | $290 to $320 | Unchanged | ||
Kuvan Net Product Revenues | $340 to $360 | Unchanged |
Select Income Statement Guidance ($ in millions, except percentages)
Item | ||||
Provided August 4, 2016 | Updated October 27, 2016 | |||
Cost of Sales (% of Total BioMarin Revenues) | 18.0% to 19.0% | Unchanged | ||
Selling, General and Admin. Expense | $470 to $490 | $460 to $480 | ||
Research and Development Expense | $670 to $690 | $650 to $670 | ||
GAAP Net Loss | $(620) to $(650) | $(600) to $(630) | ||
non-GAAP Loss | $(30) to $(50) | $(10) to $(30) |
Recent Key Program Updates
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Procter & Gamble (PG) Tops Q3 EPS by 11c, Revenues Miss
- BayCom Corp (BCML) Misses Q1 EPS by 4c
- Community West Bancshares (CWBC) Tops Q1 EPS by 7c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!